期刊文献+

Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients 被引量:1

Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients
下载PDF
导出
摘要 AIM:To investigate the virological relapse rate in hepatitis B e antigen(HBeAg)-negative patients after antiviral therapy discontinuation and analyze the factors associated with virological relapse.METHODS:Among patients diagnosed with chronic hepatitis B infection between May 2005 and July2010,204 were eligible for analysis.The Kaplan-Meier method and log-rank test were used to calculate the cumulative rate of relapse and compare cumulative relapse rates between groups.The Cox proportional hazards regression model was used to evaluate the predictive factor of virological relapse.RESULTS:The 2 and 1 year cumulative risks of virological relapse after antiviral therapy discontinuation were 79.41%(162/204) and 43.82%(71/162),respectively.Multivariate analysis revealed that only post treatment hepatitis B surface antigen(HBsAg)level was associated with virological relapse {P= 0.011).The cumulative risk of virological relapse was higher in the patients with HBsAg levels ≥1500 IU/L than in those with HBsAg levels < 1500 IU/L(P= 0.0013).The area under the curve was 0.603(P= 0.033).The cutoff HBsAg value for predicting virological relapse was 1443IU/L CONCLUSION:We found that the virological relapse rate remained high after antiviral therapy discontinuation in the HBeAg-negative patients and that the post treatment HBsAg levels predicted virological relapse. AIM:To investigate the virological relapse rate in hepatitis B e antigen(HBeAg)-negative patients after antiviral therapy discontinuation and analyze the factors associated with virological relapse.METHODS:Among patients diagnosed with chronic hepatitis B infection between May 2005 and July2010,204 were eligible for analysis.The Kaplan-Meier method and log-rank test were used to calculate the cumulative rate of relapse and compare cumulative relapse rates between groups.The Cox proportional hazards regression model was used to evaluate the predictive factor of virological relapse.RESULTS:The 2 and 1 year cumulative risks of virological relapse after antiviral therapy discontinuation were 79.41%(162/204) and 43.82%(71/162),respectively.Multivariate analysis revealed that only post treatment hepatitis B surface antigen(HBsAg)level was associated with virological relapse {P= 0.011).The cumulative risk of virological relapse was higher in the patients with HBsAg levels ≥1500 IU/L than in those with HBsAg levels < 1500 IU/L(P= 0.0013).The area under the curve was 0.603(P= 0.033).The cutoff HBsAg value for predicting virological relapse was 1443IU/L CONCLUSION:We found that the virological relapse rate remained high after antiviral therapy discontinuation in the HBeAg-negative patients and that the post treatment HBsAg levels predicted virological relapse.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第28期8653-8659,共7页 世界胃肠病学杂志(英文版)
基金 Supported by Natural Science Foundation of Jiangsu Province,China,No.BK2011515 Medical Project of Health Department Jiangsu Province,No.H201248 Preventive Medicine research projects of Jiangsu Province,No.Y2012016 the Social Development Project of Zhenjiang City,No.SH2013056
关键词 Chronic HEPATITIS B Virological RELAPSE HEPATITIS B surface ANTIGEN Chronic hepatitis B Virological relapse Hepatitis B surface antigen
  • 相关文献

参考文献26

  • 1Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y,Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y,Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransportingpolypeptide is a functional receptor for human hepatitis B and Dvirus. Elife 2012; 1: e00049 [PMID: 23150796 DOI: 10.7554/eLife.00049].
  • 2McMahon BJ. The natural history of chronic hepatitis B virusinfection. Semin Liver Dis 2004; 24 Suppl 1: 17-21 [PMID:15192797 DOI: 10.1055/s-2004-828674].
  • 3de Ruiter CJ, Van Leeuwen D, Heijblom A, Bobbert MF, de HaanA. Fast unilateral isometric knee extension torque development andbilateral jump height. Med Sci Sports Exerc 2006; 38: 1843-1852[PMID: 17019308 DOI: 10.1249/01.mss.0000227644.14102.50].
  • 4Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, GorinJM, Bonino F. Outcome of anti-HBe positive chronic hepatitis B inalpha-interferon treated and untreated patients: a long term cohortstudy. J Hepatol 2002; 36: 263-270 [PMID: 11830339].
  • 5Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H,Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF,Sabbat J. Lamivudine for patients with chronic hepatitis B andadvanced liver disease. N Engl J Med 2004; 351: 1521-1531[PMID: 15470215 DOI: 10.1056/NEJMoa033364].
  • 6Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, NgKY, Nicholls GJ, Dent JC, Leung NW. Four years of lamivudinetreatment in Chinese patients with chronic hepatitis B. JGastroenterol Hepatol 2004; 19: 1276-1282 [PMID: 15482535DOI: 10.1111/j.1440-1746.2004.03428.x].
  • 7Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, KitisG, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, BrosgartCL, Borroto-Esoda K, Arterburn S, Chuck SL. Long-term therapywith adefovir dipivoxil for HBeAg-negative chronic hepatitis Bfor up to 5 years. Gastroenterology 2006; 131: 1743-1751 [PMID:17087951 DOI: 10.1053/j.gastro.2006.09.020].
  • 8Sung JJ, Amarapurkar D, Chan HL, Cheng J, Kao JH, Han KH,Piratvisuth T. Treatment of chronic hepatitis B in Asia-Pacificcountries: is the Asia-Pacific consensus statement being followed-Antivir Ther 2010; 15: 607-616 [PMID: 20587854 DOI: 10.3851/IMP1561].
  • 9Sohn HR, Min BY, Song JC, Seong MH, Lee SS, Jang ES, ShinCM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW.Off-treatment virologic relapse and outcomes of re-treatmentin chronic hepatitis B patients who achieved complete viralsuppression with oral nucleos(t)ide analogs. BMC Infect Dis 2014;14: 439 [PMID: 25125320 DOI: 10.1186/1471-2334-14-439].
  • 10Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS,Lee CM. The role of hepatitis B surface antigen quantificationin predicting HBsAg loss and HBV relapse after discontinuationof lamivudine treatment. J Hepatol 2014; 61: 515-522 [PMID:24798617 DOI: 10.1016/j.jhep.2014.04.029].

同被引文献13

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部